GSA Capital Partners’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-17,741
| Closed | -$490K | – | 1848 |
|
|
2024
Q3 | $490K | Buy |
17,741
+16,460
| +1,285% | +$455K | 0.04% | 920 |
|
|
2024
Q2 | $37K | Sell |
1,281
-428
| -25% | -$12.4K | ﹤0.01% | 1570 |
|
|
2024
Q1 | $76K | Buy |
+1,709
| New | +$76K | 0.01% | 1510 |
|
|
2023
Q4 | – | Sell |
-1,727
| Closed | -$51K | – | 1742 |
|
|
2023
Q3 | $51K | Buy |
+1,727
| New | +$51K | ﹤0.01% | 1416 |
|
|
2023
Q1 | – | Sell |
-804
| Closed | -$56K | – | 1745 |
|
|
2022
Q4 | $56K | Buy |
+804
| New | +$56K | 0.01% | 1352 |
|
|
2022
Q2 | – | Sell |
-2,350
| Closed | -$237K | – | 1632 |
|
|
2022
Q1 | $237K | Buy |
+2,350
| New | +$237K | 0.03% | 1062 |
|
|
2021
Q3 | – | Sell |
-1,525
| Closed | -$495K | – | 1631 |
|
|
2021
Q2 | $495K | Buy |
+1,525
| New | +$495K | 0.06% | 633 |
|